Works matching AU Wrishko, Rebecca E.

Results: 13

Assessment of Bezlotoxumab Immunogenicity.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 3, p. 330, doi. 10.1002/cpdd.729

By:

Montgomery, Diana L.;
Matthews, Randolph P.;
Yee, Ka Lai;
Tobias, Lori M.;
Dorr, Mary Beth;
Wrishko, Rebecca E.

Publication type:

Article

A time-to-event analysis of the exposure–response relationship for bezlotoxumab concentrations and CDI recurrence.

Published in:

Journal of Pharmacokinetics & Pharmacodynamics, 2020, v. 47, n. 2, p. 121, doi. 10.1007/s10928-019-09660-5

By:

Yee, Ka Lai;
Kleijn, Huub Jan;
Zajic, Stefan;
Dorr, Mary Beth;
Wrishko, Rebecca E.

Publication type:

Article

1558. A Population Pharmacokinetic Model for Posaconazole Intravenous Solution and Oral Powder for Suspension Formulations in Pediatric Patients With Neutropenia.

Published in:

Open Forum Infectious Diseases, 2019, v. 6, p. S569, doi. 10.1093/ofid/ofz360.1422

By:

Winchell, Gregory A;
Greef, Rik de;
Wrishko, Rebecca E;
Mangin, Eric;
Waskin, Hetty;
Bruno, Christopher

Publication type:

Article

Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics.

Published in:

British Journal of Clinical Pharmacology, 2007, v. 63, n. 1, p. 24, doi. 10.1111/j.1365-2125.2006.02726.x

By:

Forgue, S. Thomas;
Phillips, Diane L.;
Bedding, Alun W.;
Payne, Christopher D.;
Jewell, Hayley;
Patterson, Beverley E.;
Wrishko, Rebecca E.;
Mitchell, Malcolm I.

Publication type:

Article

Tadalafil pharmacokinetics in healthy subjects.

Published in:

British Journal of Clinical Pharmacology, 2006, v. 61, n. 3, p. 280, doi. 10.1111/j.1365-2125.2005.02553.x

By:

Forgue, S. Thomas;
Patterson, Beverley E.;
Bedding, Alun W.;
Payne, Christopher D.;
Phillips, Diane L.;
Wrishko, Rebecca E.;
Mitchell, Malcolm I.

Publication type:

Article

Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.

Published in:

2019

By:

Wrishko, Rebecca E.;
McCrea, Jacqueline B.;
Yee, Ka Lai;
Liu, Wen;
Panebianco, Deborah;
Mangin, Eric;
Chakravarthy, Manu;
Martinez-Cantarin, Maria P.;
Kraft, Walter K.

Publication type:

Correction Notice

Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.

Published in:

Clinical Drug Investigation, 2019, v. 39, n. 5, p. 441, doi. 10.1007/s40261-019-00764-x

By:

Wrishko, Rebecca E.;
McCrea, Jacqueline B.;
Yee, Ka Lai;
Liu, Wen;
Panebianco, Deborah;
Mangin, Eric;
Chakravarthy, Manu;
Martinez-Cantarin, Maria P.;
Kraft, Walter K.

Publication type:

Article

Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men.

Published in:

Clinical Drug Investigation, 2018, v. 38, n. 7, p. 631, doi. 10.1007/s40261-018-0650-4

By:

Yee, Ka Lai;
McCrea, Jacqueline;
Panebianco, Deborah;
Liu, Wen;
Lewis, Nicole;
Cabalu, Tamara;
Ramael, Steven;
Wrishko, Rebecca E.

Publication type:

Article

Prediction of Prasugrel Active Metabolite Concentrations From 2 Downstream Inactive Metabolite Concentrations Using Multilinear Regression Analysis.

Published in:

Journal of Clinical Pharmacology, 2009, v. 49, n. 8, p. 973, doi. 10.1177/0091270009340416

By:

Ernest, II, C. Steven;
Heathman, Michael A.;
Wrishko, Rebecca E.

Publication type:

Article

Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON-TIMI 38.

Published in:

Journal of Clinical Pharmacology, 2009, v. 49, n. 8, p. 984, doi. 10.1177/0091270009337942

By:

Wrishko, Rebecca E.;
C. Steven Ernest, II;
Small, David S.;
Li, Ying G.;
Weerakkody, Govinda J.;
Riesmeyer, Jeffrey R.;
Macias, William L.;
Rohatagi, Shashank;
Salazar, Daniel E.;
Antman, Elliott M.;
Wiviott, Stephen D.;
Braunwald, Eugene;
Lan Ni

Publication type:

Article

Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects.

Published in:

Journal of Clinical Pharmacology, 2008, v. 48, n. 5, p. 610, doi. 10.1177/0091270008315315

By:

Wrishko, Rebecca E.;
Dingemanse, Jasper;
Yu, Albert;
Darstein, Christelle;
Phillips, Diane L.;
Mitchell, Malcolm I.

Publication type:

Article

Effect of Age on the Pharmacokinetics and Pharmacodynamics of Prasugrel during Multiple Dosing.

Published in:

Drugs & Aging, 2009, v. 26, n. 9, p. 781, doi. 10.2165/11315780-000000000-00000

By:

Small, David S.;
Wrishko, Rebecca E.;
Ernest II, C. Steven;
Lan Ni;
Winters, Kenneth J.;
Farid, Nagy A.;
Li, Ying G.;
Salazar, Daniel E.;
Payne, Christopher D.

Publication type:

Article

Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON-TIMI 38 Substudy.

Published in:

Journal of Clinical Pharmacology, 2012, v. 52, n. 6, p. 789, doi. 10.1177/0091270011406280

By:

Riesmeyer, Jeffrey S.;
Salazar, Daniel E.;
Weerakkody, Govinda J.;
Ni, Lan;
Wrishko, Rebecca E.;
Ernest, C. Steven;
Luo, Junxiang;
Li, Ying G.;
Small, David S.;
Rohatagi, Shashank;
Macias, William L.

Publication type:

Article